Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on July 27, 2026.
reiterateNYSE:NUVB
HC Wainwright & Co. Reiterates Buy Rating on Nuvation Bio Inc. (NUVB)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) on July 27, 2026.
Market Context
Nuvation Bio Inc. operates in the Healthcare sector. The stock currently trades at $6.61 with a market capitalization of $2.8B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Nuvation Bio Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Nuvation Bio Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 27, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 23, 2026 | Wedbush | Outperform | N/A |
| Jul 07, 2026 | RBC Capital | Outperform | N/A |
| Jul 07, 2026 | Truist Securities | Buy | N/A |
| May 05, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View NUVB Stock Page
Frequently Asked Questions
What does a Buy rating mean for NUVB?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on Nuvation Bio Inc. (NYSE:NUVB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NUVB forecast page.